DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition
Open Access
- 17 October 2023
- journal article
- research article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 164, 106477
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
- Medical Research Council
This publication has 37 references indexed in Scilit:
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsCancer Discovery, 2017
- Classification and characterization of microsatellite instability across 18 cancer typesNature Medicine, 2016
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaNew England Journal of Medicine, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Exploiting DNA mismatch repair deficiency as a therapeutic strategyExperimental Cell Research, 2014
- cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STINGNature, 2013
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Beta2‐microglobulin mutations in microsatellite unstable colorectal tumorsInternational Journal of Cancer, 2007
- Control of self‐reactive cytotoxic T lymphocytes expressing γδ T cell receptors by natural killer inhibitory receptorsEuropean Journal of Immunology, 1997